LECAP Asset Management’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
Sell
-1,019
Closed -$937K 330
2026
Q1
$937K Sell
1,019
-243
-19% -$246K 0.35% 122
2025
Q4
$1.36M Sell
1,262
-455
-26% -$435K 0.54% 65
2025
Q3
$1.31M Buy
+1,717
New +$1.28M 0.46% 86
2025
Q2
Sell
-637
Closed -$526K 353
2025
Q1
$526K Sell
637
-1,708
-73% -$1.42M 0.12% 229
2024
Q4
$1.81M Sell
2,345
-263
-10% -$218K 0.49% 75
2024
Q3
$2.31M Buy
2,608
+1,848
+243% +$1.66M 0.5% 68
2024
Q2
$688K Buy
+760
New +$608K 0.15% 227
2024
Q1
Sell
-689
Closed -$402K 346
2023
Q4
$402K Buy
+689
New +$402K 0.15% 230

Other funds holding LLY

LECAP Asset Management's LLY Position: Q2 2026 in Review

LECAP Asset Management sold out of Eli Lilly (LLY) in Q2 2026, closing a stake of 1,019 shares — an estimated $937K sold.

LECAP Asset Management first reported a position in LLY in Q4 2023 and held it in 8 quarters. The position peaked at $2.31M in Q3 2024. 4,624 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • LECAP Asset Management reported no remaining Eli Lilly position as of Q2 2026 after selling out during the quarter.
  • LECAP Asset Management sold 1,019 Eli Lilly shares in Q2 2026, an estimated $937K.
  • LECAP Asset Management first reported a position in Eli Lilly in Q4 2023 and held it in 8 quarters.
  • LECAP Asset Management's Eli Lilly position peaked at $2.31M in Q3 2024.
  • 4,624 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on LECAP Asset Management's 13F filing for Q2 2026, filed 30 Jul 2026.